These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24926820)

  • 1. Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing's disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentiation.
    Occhi G; Regazzo D; Albiger NM; Ceccato F; Ferasin S; Scanarini M; Denaro L; Cosma C; Plebani M; Cassarino MF; Mantovani G; Stalla GK; Pecori Giraldi F; Paez-Pareda M; Scaroni C
    Endocrinology; 2014 Sep; 155(9):3538-49. PubMed ID: 24926820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function.
    Gentilin E; Tagliati F; Terzolo M; Zoli M; Lapparelli M; Minoia M; Ambrosio MR; Degli Uberti EC; Zatelli MC
    J Endocrinol; 2013 Sep; 218(3):275-85. PubMed ID: 23814013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cold inducible RNA binding protein upregulation in pituitary corticotroph adenoma induces corticotroph cell proliferation via Erk signaling pathway.
    Jian F; Chen Y; Ning G; Fu W; Tang H; Chen X; Zhao Y; Zheng L; Pan S; Wang W; Bian L; Sun Q
    Oncotarget; 2016 Feb; 7(8):9175-87. PubMed ID: 26824322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the ERK pathway for the treatment of Cushing's disease.
    Zhang D; Bergsneider M; Wang MB; Heaney AP
    Oncotarget; 2016 Oct; 7(43):69149-69158. PubMed ID: 27708250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease.
    Castillo V; Theodoropoulou M; Stalla J; Gallelli MF; Cabrera-Blatter MF; Haedo MR; Labeur M; Schmid HA; Stalla GK; Arzt E
    Neuroendocrinology; 2011; 94(2):124-36. PubMed ID: 21525729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
    van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine cushing's disease.
    de Bruin C; Hanson JM; Meij BP; Kooistra HS; Waaijers AM; Uitterlinden P; Lamberts SW; Hofland LJ
    Endocrinology; 2008 Sep; 149(9):4357-66. PubMed ID: 18483151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ghrelin stimulates adrenocorticotrophic hormone (ACTH) secretion by human ACTH-secreting pituitary adenomas in vitro.
    Pecori Giraldi F; Bucciarelli LG; Saccani A; Scacchi M; Pesce S; Losa M; Cavagnini F
    J Neuroendocrinol; 2007 Mar; 19(3):208-12. PubMed ID: 17280594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
    Teshima T; Hara Y; Takekoshi S; Teramoto A; Osamura RY; Tagawa M
    Domest Anim Endocrinol; 2009 Jan; 36(1):3-12. PubMed ID: 18818046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nur77 gene expression levels were involved in different ACTH-secretion autonomy between Cushing's disease and subclinical Cushing's disease.
    Tabuchi Y; Kitamura T; Fukuhara A; Mukai K; Onodera T; Miyata Y; Hamasaki T; Oshino S; Saitoh Y; Morii E; Otsuki M; Shimomura I
    Endocr J; 2016 Jun; 63(6):545-54. PubMed ID: 27025408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
    Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP
    J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas.
    Sekizaki T; Kameda H; Nakamura A; Kuwabara S; Nomoto H; Cho KY; Ishi Y; Motegi H; Miyoshi H; Atsumi T
    Pituitary; 2023 Oct; 26(5):597-610. PubMed ID: 37642928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
    Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
    Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential role for retinoic acid in patients with Cushing's disease.
    Pecori Giraldi F; Ambrogio AG; Andrioli M; Sanguin F; Karamouzis I; Corsello SM; Scaroni C; Arvat E; Pontecorvi A; Cavagnini F
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3577-83. PubMed ID: 22851491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
    Batista DL; Zhang X; Gejman R; Ansell PJ; Zhou Y; Johnson SA; Swearingen B; Hedley-Whyte ET; Stratakis CA; Klibanski A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4482-8. PubMed ID: 16940446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid as a novel medical therapy for Cushing's disease in dogs.
    Castillo V; Giacomini D; Páez-Pereda M; Stalla J; Labeur M; Theodoropoulou M; Holsboer F; Grossman AB; Stalla GK; Arzt E
    Endocrinology; 2006 Sep; 147(9):4438-44. PubMed ID: 16740975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of somatostatin analogs in Cushing's disease.
    van der Hoek J; Lamberts SW; Hofland LJ
    Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
    Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why don't corticotroph tumors always produce Cushing's disease?
    García-Martínez A; Cano DA; Flores-Martínez A; Gil J; Puig-Domingo M; Webb SM; Soto-Moreno A; Picó A
    Eur J Endocrinol; 2019 Sep; 181(3):351-361. PubMed ID: 31319379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.